Phio Pharmaceuticals Corp. PHIO 深 沪
已收盘 08-01 16:00:00 美东时间
2.33
-0.050
-2.10%
华盛通- 最 高2.41
- 今 开2.41
- 成交量 22.10万股
- 最 低 2.27
- 昨 收 2.38
- 总市值 1117.98万
- 52周最高 9.79
- 市盈率 静 --
- 换手率 4.61%
- 52周最低 0.9657
- 委 比 -72.69%
- 总股本 479.82万
- 历史最高 3118.50
- 量 比 0.02
- 振 幅 5.88%
- 历史最低 0.9657
- 每 手 1
- 风险率 2.40%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Phio Pharmaceuticals Issues New Warrants for $2.5M
Phio Pharmaceuticals ( ($PHIO) ) just unveiled an update. On July 25, 2025, Phi...
07-31 04:51
Phio Pharmaceuticals Announces New Manufacturing Agreement
Phio Pharmaceuticals ( ($PHIO) ) just unveiled an announcement. On July 25, 202...
07-26 01:57
Phio Pharmaceuticals shares are trading higher after the company announced a comprehensive U.S. drug substance development services agreement for its lead compound PH-762.
Phio Pharmaceuticals shares are trading higher after the company announced a co...
07-25 20:46
美股大行评级 | 潜在涨幅312.09%！HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级
潜在涨幅312.09%！HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级；联邦快递遭多家机构下调目标价>>
06-26 08:38
1. Phio Pharma CEO To Present New Skin Cancer Data On Groundbreaking Gene-Silencing Therapy PH-762
Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today
06-24 19:47
美股大行评级 | 潜在涨幅6326.33%！Ascendiant Capital上调Plus Therapeutics目标价至20.5美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1137665801621229569.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Ascendiant Capital：维持Plus Therapeutics(PSTV)"买入"评级，目标价从20美元升至20.5美元</p> <p>• Ascendiant Capital：维持RenovoRx(RNXT
06-06 09:45
HC Wainwright & Co. Assumes Phio Pharma at Buy, Announces Price Target of $14
HC Wainwright & Co. analyst Joseph Pantginis assumes Phio Pharma (NASDAQ:PHIO) with a Buy rating and announces Price Target of $14.
06-05 19:11
Phio Pharma To Present Update On Proprietary INTASYL Sirna Technology And Progress On On-Going Clinical Trial With Lead Compound PH-762 For Treatment Of Skin Cancers
Registration Link for Presentation to take place Thursday, May 22, 2025 at 10:00 AM ETMarlborough, Massachusetts--(Newsfile Corp. - May 19, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA
05-19 19:50
Phio Pharma Q1 EPS $(0.47) Down From $(0.41) YoY
Phio Pharma (NASDAQ:PHIO) reported quarterly losses of $(0.47) per share. This is a 14.63 percent decrease over losses of $(0.41) per share from the same period last year.
05-16 04:46
Phio Pharmaceuticals Reports Positive Phase 1b Trial Results
The latest update is out from Phio Pharmaceuticals ( ($PHIO) ). On May 7, 2025,...
05-08 05:16
